Summary Inflammation may promote malignant invasion by enhancing cancer cell-associated proteolysis. Here we present the effect of inflammatory cytokines on the plasminogen activation system of eight human colon carcinoma cell lines. Tumour necrosis factor a (TNF-a) and interleukin-l,B (IL-1,B) increased in several, but not all, cell lines the production of urokinase-type plasminogen activator (uPA), tissue-type PA (tPA) and plasminogen activator inhibitor type 1 (PAI-1) as analysed by zymography, enzyme immunoassays and Northern analysis. Interleukin 6 (IL-6) had no effect. uPA receptor (uPAR) mRNA levels were also upregulated. However, each individual cell line responded differently following exposure to TNF-a or IL-l,i. For example, there was a dose-dependent up-regulation of uPA and PAI-1 in SW 620 cells, whereas increased uPA production in SW 1116 cells was not accompanied by an increase in PAI-1. The TNF-a stimulatory effect was blocked by anti-TNF-a Fab fragments. All cell lines expressed both types of TNF receptor mRNAs, whereas no transcript for TNF-a, IL-1If, IL-6, IL-6 receptor or the IL-1 receptors was found. Our results demonstrate that TNF-a and IL-l, stimulate the plasminogen activation system in tumour cells but the responses differed even in cells derived from the same tissue origin.
Tumour-associated macrophages recruited by the inflammatory reaction associated with cancer diseases have been suggested to favour or, alternatively, to interfere with the invasive growth of cancer cells (Mantovani et al., 1992; Dingemans et al., 1993; Levine and Saltzman, 1990 ; Van der Boschet et al., 1992; Orosz et al., 1993; Quin et al., 1993) . These conflicting observations are possibly related to the pleiotropic biological effects mediated by cytokines produced by the host in response to tumour invasion and metastasis.
TNF-a, IL-l# and IL-6 are typical multifunctional cytokines secreted mainly by monocyte-macrophages of the solid tumour mononuclear infiltrate. Tumour cell membrane vesicles were found to induce the release of macrophage TNF-oa (Hasday et al., 1990) . This may explain that high plasma concentrations of inflammatory cytokines and blood mononuclear cell cytokine mRNA levels, in particular of TNF-a, were found in gastrointestinal cancer patients (Balkwill et al., 1987; Nakazaki, 1991) . Moreover, in situ hybridisation studies of samples obtained from colon cancer patients have identified TNF-a-producing cells as belonging to the macrophage lineage, whereas IL-13 and IL-6 were less frequently detected (Beissert et al., 1989; Naylor et al., 1990) . This pattern of TNF-a expression is also observed in breast cancer (Miles et al., 1994) . In contrast, in ovarian cancer, TNF-a mRNA is found in epithelial tumour cells and in infiltrating macrophages (Naylor et al., 1993) . Local destructive growth and dissemination of cancer cells is dependent on effective proteolysis of surrounding extracellular matrices. There is much evidence suggesting that PAs and their respective inhibitors regulate peritumoral tissue breakdown. In addition, clinical investigations have shown that the plasminogen activation system may be of importance in the prognostic assessment of colon cancer (Ganesch et al., 1994 governing the proteolytic activity of cancer cells, thus facilitating or inhibiting the spread of malignancy (Masure and Opdenakker, 1989; Opdenakker and Damne, 1992) .
In this study, we investigated the effects of TNF-a, IL-Ip and IL-6 on the plasminogen activation system in neoplastic cells, all derived from the colorectal tissue. We found that TNF-a and, less markedly, IL-1If, increased the production of PAs, PAI-1 and uPAR in eight human colon carcinoma cell lines, whereas IL-6 had no effect. More interestingly, we observed that the stimulatory effect differed for each cell line. The pattern of response was not dependent on the cytokine or cytokine receptor expression of colon cancer cells.
Materials and methods
Cell culture Eight human colon carcinoma cell types were studied: HT 29, SW 480, COLO 205, SW 620, SW 1116 were from the American Type Culture Collection (Rockville, MD, USA), while COSUT, CO 112 and CO 115 were established in our laboratory (Cajot et al., 1986; Tran-Thang et al., 1994) . HT 29, CO 112 and CO 115 cells were grown to confluency in Dulbecco's modified Eagle medium (DMEM) supplemented with 5% heat-inactivated fetal calf serum (FCS), 4 mM Lglutamine, 100 IU ml-' penicillin and 100 ug ml-1 streptomycin; SW 480, SW 620, SW 1116 were maintained in Leibovitz's L-15 medium, and COSUT in McCoy's 5A. Both media were supplemented with 10% FCS, 4 mM L-glutamine and antibiotics. Cells were trypsinised with 7 ml trypsin-EDTA and neutralised with 8 ml of FCS-containing culture media, plated at 2 or 4 x 106 cells per well in 6-or 12-well plates, and left overnight in FCS-containing media. Cells were washed three times in serum-free culture medium and incubated for 24 h in the absence or presence of cytokine under defined experimental conditions. Conditioned media were collected for sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) Serum-free conditioned media were collected by centrifugation at 4400 g for 10 min and stored at -80°C until thawing for SDS-PAGE zymographic analysis (Tran-Thang et al., 1994; Heussen and Dowdle, 1980) and PA, PAI antigen determinations using EIAs according to the manufacturer's recommendations (TintElize for uPA, tPA, PAI-I and PAI-2 from Biopool, Umea, Sweden).
Northern blot analysis PolyA+ RNA extracted from cell lines, electrophoresed under denaturing conditions using formaldehyde and formamide, was transfered to nitrocellulose. Blots were hybridised to human uPA, uPAR, tPA, PAI-1, PAI-2 and mouse P-actin cDNA fragment probes as previously described (Tran-Thang et al., 1994) . For cytokine and cytokine receptor expression, the following probes were used: a 1 kb HindIII-EcoRI fragment from human TNF-cx cDNA, a 300 bp PstI-EcoRI fragment from human IL-1# cDNA, a 298 bp Xbal-SalI fragment from human IL-6 cDNA (A Shaw, Glaxo, Geneva), PCR-generated cDNA fragments of the 55 kDa or 75 kDa human TNF-a receptor (TNF-R, or TNF-R2) were obtained as previously described (Tada et al., 1994) , a 477 bp HindIII-EcoRI cDNA fragment from human IL-1 type 1 receptor (IL-i-RI) (Sims et al, 1988) , and a 750 bp EcoRISall cDNA fragment from human IL-1 type 2 receptor (IL-1-R2) (McMahan, 1991) (kindly provided by Dr J E Sims, Immunex, Seattle, Washington, USA), a 1.7 kb PstI digest of human IL-6-R cDNA (Yamasaki et al., 1988 ) (obtained from Dr T Kishimoto, Division of Immunology, Yamada-Oka, Suita, Osaka, Japan).
Results
TNF-cx and IL-/I, modulate the plasminogen activation system of human colon carcinoma cells Serum-free conditioned media from eight colon carcinoma cell lines, incubated for 24 h in the absence or presence of TNF-cx (20 ng ml-') or IL-I# (5 ng ml-'), were subjected to SDS-PAGE zymographic analysis. Figure 1 shows the conditioned media of the analysed colon carcinoma cell lines stimulated with TNF-a or with IL-1I3. These The modulation of the plasminogen activation system induced by TNF-a is dose dependent and can be inhibited by anti-TNFa Fab fragments TNF-a increased uPA and PAI-I mRNA levels in SW 620 cells, but only uPA mRNA levels in SW 1116 cells (see Figure 2 ). The TNF-a effect was further studied in these two cell lines. TNF-cx enhanced the production of uPA and PAI-I antigen in SW 620 cells (Figure 3 , upper part). The effect was dose dependent and was already observed between 0.4 and 2 ng ml -. SW 1116 cells were less sensitive to TNF-a, since the uPA increase required higher cytokine concentrations (2-20 ng ml-1). Furthermore, in SW 1116 cells, PAI-I antigen levels remained unchanged at TNF-a concentrations up to 40 ng ml-'. Zymographic analysis showed that TNF-a also stimulated tPA production in SW 1116 cells. The low molecular weight uPA lysis band was also present at high TNF-ac concentrations in the case of SW 1116 cells (Figure 3 , lower part). The TNF-cx-mediated increased production of uPA in SW 1116 cells was inhibited by Fab fragments directed against TNF-a but not by non-immune Fab fragments. On the other hand, the PAI-I production remained unchanged by TNF-a treatment in the presence or absence of anti-TNF-ax or nonimmune Fab fragments (Figure 4 ). This indicates that the observed effects were caused by TNF-a and not by contaminants in the TNF-cx preparation.
The human colon carcinoma cells express the two types of TNF-a receptors The variant behaviour of the colon carcinoma cell lines could have been caused by a different expression of inflammatory cytokines or cytokine receptors. Therefore, we analysed their expression by Northern analysis. All cell types expressed, in varying amounts, the 55 and 75 kDa types of TNF receptors (TNF-R, and -R2). There was no correlation between the expression levels of the two types of TNF receptors. For example, SW 480 and SW 620 expressed similar levels of TNF-RI, but differed significantly in TNF-R2 expression levels ( Figure 5 ). In addition, there was no relationship between the pattern of TNF receptor expression and the extent of modulation of the plasminogen activation system by TNF-a. Even after prolonged autoradiography, no signal was obtained for TNF-cx, IL-I#, IL-6 and receptors for IL-1 and IL-6.
Discussion
A broad spectrum of acute-phase proteins are synthesised during inflammation and their expression has been shown to be modulated by TNF-a, IL-,IB and IL-6 (Perlmutter et al., 1986; Heinrich et al., 1990) . In the present study, we have shown that exposure of human colon carcinoma cells to the inflammatory cytokines, TNF-a and IL-,IB, increases the production of proteins that regulate tumour cell-mediated plasminogen activation. The augmented generation of uPA, tPA, PAI-I and uPAR was demonstrated by SDS-PAGE zymography (Figure 1 ), antigen determination (Table I) and RNA analysis (Figure 2) (Loskutoff, 1991; Healy and Gelehrter, 1994) . Remarkably, IL-6 had no effect on all eight colon carcinoma cells lines examined (data not shown). In HepG2 human hepatoma cells, TNF-a and IL-1# have been reported to increase uPA or PAI-1 levels, whereas IL-6 did not (Healy and Gelehrter, 1994) . Little is known about the effect of IL-6 on the plasminogen activation system in cancer cells. Our findings suggest that, at least in colon carcinoma cells, the plasminogen activation system is unresponsive to IL-6. TNF-a has been reported to modulate the expression of the PAs, PAIs and uPAR in various normal and malignant cells (Schleef et al., 1988; Van Hinsbergh et al., 1990; Niedbala and Picarella, 1992; Marshall et al., 1992; Medcalf et al., 1988; Waltz et al., 1993; Sitrin et al., 1994; Georg et al., 1989; Vassalli, 1992) . We studied the effects of TNF-a in detail and demonstrated a dose-dependent TNF-a-induced increase in the plasminogen activation system of colon carcinoma cells (Figure 3) . Similar results have been reported in tumour cell lines originating from different tissue types (Georg et al., 1989) . The concentration range of TNF-oa used by us and others (Medcalf et al., 1988; Georg et al., 1989) was similar to those found in sera of cancer patients (Balkwill et al., 1987) . Of particular interest, we showed that even in cancer cells derived from the same tissue type, i.e. colon carcinoma cells, the pattern of response to cytokine stimulation differed greatly depending on the cell line (Table I and Figure 2) . Therefore, hypotheses on the biological role of inflammatory mediators acting on the modulation of cancer cell-associated proteolyis should not be drawn from observations made in one particular cell line or in a limited number of tumour cell types. On the other hand, our findings may explain the contradictory observations which suggest that TNF-a can facilitate or alternatively inhibit tumour progression (Orosz et al., 1993; Quin et al., 1993) .
We further characterised the cytokine and cytokine receptor profiles of the eight colon carcinoma cell types ( Figure 5 ). All cell lines expressed the two types of TNF receptor transcripts as evidenced by Northern analysis. Our observation is in agreement with the identification of both TNF receptors in the majority of cell types and tissues (Loescher et al., 1990; Schall et al., 1990; Smith et al., 1990) .
It is possible, however, that in vivo, low levels of TNF-a receptor expression preclude their identification as in the case of breast cancer (Miles et al., 1994) . TNF-cx, IL-,IB and IL-6 transcripts were not detectable, nor were those of IL-1 and IL-6 receptors. To our knowledge, there are only a few reports dealing with cytokine and cytokine receptor expression in colon carcinoma cell lines (Gaffney et al., 1988; Jung et al., 1995) . Expression of a large variety of cytokine and cytokine receptor genes was reported in melanoma and sarcoma tumours but using the polymerase chain reaction (Colombo et al., 1992; Pekarek et al., 1993; Mattei et al., 1994) . In colon cancer patient tissue samples, TNF-a RNA expression was localised, by in situ hybridisation, in tumour-infiltrating stromal macrophages (Beissert et al., 1989; Naylor et al., 1990) . No TNF-a transcript was detected in the eight human colon carcinoma cell lines and using a cytotoxic/cytostatic assay involving TNF-susceptible WEHI 164 fibrosarcoma cells, we found no TNF-adependent activity in 10-fold concentrated conditioned media (data not shown). All these cell lines responded to TNF-ac by increasing the expression of proteins implicated in the plasminogen activation.
We observed that colon carcinoma cell lines which responded to IL-1I,, did not exhibit detectable levels of its receptors. There are two known receptors for IL-1, the type 1 is believed to mediate the biological responses, whereas the function of the type 2 receptor is still unclear (Sims et al., 1989; Deyerle et al., 1992; Sims et al., 1993 (Imamura et al., 1987) , as well as protease-mediated shedding of TNF-R (Ding and Porteu, 1992) , followed by resynthesis of newly formed receptors by monocytes under TNF-ax stimulation have been described. How such putative regulation may affect the plasminogen activation system expression in colorectal carcinoma cells is not known. The TNF-R55-mediated signalling pathway has been elucidated but the role of TNF-R75 is still under debate (Heller and Kronke, 1994) . How the signal mediated by these two receptors modulates the transcriptional activity of the plasminogen activation system also remains unclear. It is suggested that TNF-R75 Plasninogen actni o by cytokcine colon cancer C Tran-Thang et al 851 might recruit TNF-x for signalling through TNF-R55 (Tartaglia et al.. 1993) 
